china dihexa powder Liaoning Xinda Talcum for Plastics & Industrial Use bulk dihexa peptide powder BPC

In MANY cases, the neurotoxic accumulation of poisons based on individual genetics gets overlooked in medication withdrawal

doi: 10.1089/adt.2022.088

Heres how they work together: Folates role: Dietary folate converts to 5-MTHF (active folate) via the MTHFR enzyme 5-MTHF donates a methyl group to homocysteine This requires B12 as a cofactor for the enzyme methionine synthase The result: homocysteine converts to methionine B12s role: B12 (as methylcobalamin) acts as a cofactor for methionine synthase It helps transfer the methyl group from 5-MTHF to homocysteine Without adequate B12, folate gets trapped and cant donate its methyl group This is called the methyl trap What happens when one is deficient: Low B12 with adequate folate: Folate cant function properly (methyl trap) Homocysteine rises despite good folate levels Methylation slows down Can mask B12 deficiency symptoms initially Low folate with adequate B12: Not enough methyl groups available for donation Homocysteine rises Methylation impaired DNA synthesis affected Both low: Severe methylation impairment Very high homocysteine Anemia (megaloblastic) Neurological damage risk Why MTHFR mutations affect this partnership: With MTHFR mutations: Your body cant efficiently convert folate to 5-MTHF This creates a bottleneck in the methylation cycle Even with adequate B12, you dont have enough active folate to work with it Result: elevated homocysteine, poor methylation The solution: Bypass the MTHFR bottleneck by taking pre-methylated folate (5-MTHF) that doesnt require conversion

This makes them suitable for a proof-of-concept trial: there is real variation to detect, and a real-world population that would benefit from better intervention options

Comparing them is more useful for understanding the evidence hierarchy in drug development than for choosing between two equivalent options